May 30, 2012
Statement from HHS Secretary Kathleen Sebelius on the reauthorization of Food and Drug Administration user fee programs
HHS applauds both houses of Congress for taking bipartisan action to reauthorize and expand the Food and Drug Administration user fee programs, building on recommendations developed by the FDA, along with consumer groups and pharmaceutical and medical device industries.
These programs ensure the FDA has the needed resources to conduct reviews of important medical products in a timely fashion, as well as provide new measures to improve the safety of the drug supply chain. Reauthorization encourages companies to continue to explore innovative new therapies and drug treatments. We look forward to working with both chambers as they resolve the differences between their two bills, so the good work of the FDA can continue.
Note: All HHS press releases, fact sheets and other news materials are available at http://www.hhs.gov/news.
Last revised: April 4, 2014